Browse studies

Find your next paid study

27,333 recruiting studies available now

Edwards PASCAL Transcatheter Tricuspid Valve Repair System Coverage With Evidence Development Study (The CLASP III TR CED Study)

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who rec…

Tricuspid RegurgitationHeart Valve DiseasesHeart Diseases+2 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Edwards LifesciencesNCT07859709

Observational

Identifying Challenges to Healthy Aging in Persons With HIV Age 50 and Older

The primary objective of this study is to identify and characterize frailty and pre-frailty in persons age 50 and older living with human immunodeficiency viru…

HIVAging

Estimated

~$10 – $750

Actual pay is set by the research site.

Wake Forest University Health SciencesNCT05858034

Fabry Disease Registry Protocol

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry …

Fabry Disease

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Genzyme, a Sanofi CompanyNCT00196742

Phase 3

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for th…

Non-squamous, Non-Small Cell Lung Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Candel Therapeutics, Inc.NCT07660094

Phase 1

A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Advanced Solid Tumours

Estimated

~$150 – $4,500

Actual pay is set by the research site.

EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesNCT05701527

Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network

This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent…

Primary HyperoxaluriaDent DiseaseAPRT Deficiency+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT02026388

Effect of Antipyretics in Gait Fatigue in Multiple Sclerosis

The goal of this observational study is to compare the impact of an antipyretic, acetaminophen to a placebo on gait fatigue in persons with multiple sclerosis …

Multiple Sclerosis

Estimated

~$10 – $750

Actual pay is set by the research site.

Hunter College of City University of New YorkNCT07440446

Phase 1

Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patien…

Myelodysplastic Syndromes

Estimated

~$150 – $3,000

Actual pay is set by the research site.

West Virginia UniversityNCT06923488

Observational

Recovery From Post-Stroke Aphasia With rTMS Targeting the Anterior Temporal Lobe: Interhemispheric Activation Changes and Lesion-Connectome-Based Predictive Outcomes

This project aims to tailor repetitive Transcranial Magnetic Stimulation (rTMS) target to the clinical profile of post-stroke aphasia, specifically focusing on…

StrokeAphasia

Estimated

~$10 – $750

Actual pay is set by the research site.

University of South CarolinaNCT07608588

Alport Syndrome Foundation Alport Patient Registry

Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US…

Alport SyndromeThin Basement Membrane DiseaseHereditary Nephritis

Estimated

~$10 – $750

Actual pay is set by the research site.

Alport Syndrome FoundationNCT06526741

Phase 2

A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung can…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$75 – $3,000

Actual pay is set by the research site.

SWOG Cancer Research NetworkNCT06031688

A Multi-Modal Wearable Sensor for Early Detection of Cognitive Decline and Remote Monitoring of Cognitive-Motor Decline Over Time

This observational study will enroll approximately 100 participants evenly split by cognitive status (Cognitively Impaired vs Non-Cognitively Impaired), and in…

Mild Cognitive Impairment (MCI)Older Adults With Cognitive DeclineOlder Adults

Estimated

~$10 – $1,125

Actual pay is set by the research site.

BioSensicsNCT07780162